Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home News Macro

Trump Excludes Generics From Big Pharma Tariff Plan

by Team Lumida
October 9, 2025
in Macro
Reading Time: 3 mins read
A A
0
woman in white dress shirt and black pants standing near brown wooden shelf

Photo by National Cancer Institute on Unsplash

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways

Powered by lumidawealth.com

  • The Trump administration announced it will not impose tariffs on generic drugs amid a national-security tariff investigation under Section 232 of the Trade Expansion Act.
  • This decision narrows the scope of pharmaceutical tariffs, focusing on name-brand drugs while excluding generics, which make up about 90% of U.S. dispensed medicines and are largely imported from countries like India.
  • The move reverses earlier indications that generics would be targeted and contrasts with Trump’s 2023 campaign pledge to bring all essential medicine production back to the U.S.
  • Administration officials caution that tariffs on generics could raise drug prices and cause shortages, as generics are cheap to produce abroad, making U.S. manufacturing less competitive even with tariffs.
  • Some Commerce Department officials and protectionists argue tariffs and government support might be necessary to reshore generic drug production and reduce reliance on foreign supply chains.
  • The administration is also considering other measures, such as federal grants or loans, to encourage domestic manufacturing of critical generic drugs.

What happened?

After months of debate, the administration decided against tariffs on generic drugs, citing concerns about consumer impact and the economics of production. The decision reflects the complexity of balancing national security, healthcare costs, and supply chain resilience.

Why it matters

Generic drugs are critical to U.S. healthcare affordability and access. Excluding them from tariffs avoids immediate price hikes and shortages but leaves open questions about long-term supply chain security. For investors, the decision affects pharmaceutical sector dynamics, trade policy risks, and potential government support programs for domestic manufacturing.

What’s next?

Monitor potential executive actions or legislation supporting domestic generic drug production. Watch for further trade negotiations and tariff policy updates. Investor focus should include pharmaceutical supply chain developments, pricing trends, and government incentives impacting drugmakers.

Source
Previous Post

Trump Calls for Jailing of Chicago Mayor and Illinois Governor

Next Post

The 2026 Tax Brackets Are Here

Recommended For You

Senate Passes the BAAJA Permitting Bill 62-33, Splitting Democrats, in a Push to Speed Energy and Data-Center Projects

by Team Lumida
8 hours ago

The Senate voted 62-33 on Thursday to pass the BAAJA permitting bill, which now heads to the House with President Donald Trump’s support.

Read more

Fed Governor Lisa Cook Says Inflation Has Been Above Target for More Than Five and a Half Years and Warns Against Waiting to Hike

by Team Lumida
8 hours ago

Lisa Cook said Friday that inflation has been above target for more than five and a half years and that waiting to raise rates risks larger increases later.

Read more

Gold Falls 2.81% to $3,520, Heading for Its Worst Week in Eight Months, Down About 8.9%, as Rate-Hike Bets Overwhelm Haven Demand

by Team Lumida
8 hours ago

Spot gold fell 2.81% to $3,520.05 on Friday, on track for its worst week in eight months, down about 8.9%, as December Fed hike bets weighed on bullion.

Read more

Treasury Yields Tumble, With the 10-Year Down 12 Basis Points to 4.932%, as Investors Flee to Havens Ahead of a Likely December Fed Hike

by Team Lumida
8 hours ago

The 10-year Treasury yield fell 12 basis points to 4.932% and the 2-year dropped more than 14 basis points to 4.634% as stocks sold off on Friday.

Read more

Gold Hovers Near $3,725, Close to Its Lowest Close Since September 2025, as Fed Minutes Show Nearly All Officials Expect More Rate Hikes

by Team Lumida
2 days ago

Gold traded near $3,725 an ounce, close to a 14-month low and down about 30% since the US-Iran war began, as the Fed signaled more rate hikes.

Read more

Foreign Holdings of US Treasuries Fall $75.5 Billion to $9.24 Trillion, the Biggest Drop Since March, Even as South Korean Investors Buy a Record $11.5 Billion

by Team Lumida
2 days ago

Foreign holdings of Treasuries fell $75.5 billion in September to a one-year low, led by China and France, while Korean investors bought a record amount.

Read more

Fed’s Waller Says the Fed May Need to ‘Shock People’ With a Half-Point Hike in December, Sending the 2-Year Treasury Yield Up More Than 4 Basis Points to 4.83%

by Team Lumida
3 days ago

Waller said a 50 basis point hike is probably needed at the Dec. 8-9 meeting, and the 2-year Treasury yield jumped more than 4 basis points to 4.83%.

Read more

Treasuries Gain for a Third Day as the 10-Year Yield Slips 3 Basis Points to 5.08%, With Traders Saying Much of the Fed’s Coming Rate Hikes Is Already Priced In

by Team Lumida
3 days ago

US Treasuries edged higher for a third day, with the 10-year yield down 3 basis points to 5.08% and the 2-year at 4.78%, as hike expectations look priced...

Read more

Iran Says It Struck U.S. Drone and Missile Sites in Kuwait as Gulf Attacks Mount, Yet WTI Settles Down 1.2% at $84.90 and Brent Slips to $92.70 on Recovering Hormuz Flows

by Team Lumida
3 days ago

Iran claimed strikes on U.S. sites in Kuwait as the war enters its ninth month, but crude settled lower on signs of recovering Hormuz flows.

Read more

Trump, Xi and Putin Converge on Shenzhen for APEC With a Trade Truce Expiring in January 2027, $30 Billion of Promised Tariff Cuts Unscheduled and Nvidia’s China Chip Scandal in the Background

by Team Lumida
3 days ago

Trump and Xi are expected to meet in Shenzhen this week to implement their trade deal, with Nvidia chips, tariffs and the Iran war all in play.

Read more
Next Post
a sign that says pay your tax now here

The 2026 Tax Brackets Are Here

a close up of a pair of jeans with a label on it

Levi Strauss Raises Fiscal-Year Outlook as Turnaround Drives Growth

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

turned on flat screen monitor

Treasury Bonds Close January Higher Despite Trump’s Tariff Threats

January 31, 2025
China’s AI Startups Challenge Global Leaders Amid U.S. Trade Curbs

How a Chinese AI Company Accessed Nvidia’s Top Chips Through an Indonesian Data Center

November 13, 2025

How Options Trading Catapulted Nvidia’s Market Cap by $350 Billion

June 3, 2024

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Legacy
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Opinions
    • Investing Philosophy
    • Op-Ed
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Investing Philosophy
  • Latest
  • Legacy
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Op-Ed
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bank of America China Commercial Real Estate CPI data centers Donald Trump EARNINGS ELON MUSK Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Novo Nordisk Nuclear Energy Nvidia oil OpenAI private equity S&P 500 SEC Semiconductor stock market stock surge Tech Stocks tesla Trump Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018